Researchers challenge NIH screening of grants for disfavored viewpoints

Class action lawsuit seeks to stop NIH censorship and termination of federally funded scientific research

Nicole Saphier unfit to serve as Surgeon General

CSPI President Peter Lurie argues Nicole Saphier is unfit to serve as Surgeon General, citing investments in Philip Morris and other health-damaging industries.

Peter's Memo: ‘Best-by’ dates are past their prime

‘Best-by’ and ‘sell-by’ dates are confusing, contribute to food waste, and they’re not designed to give consumers the info they need about food safety. There’s a better way.

Newsom urged to sign AB2030 supplement restriction for minors

California AB-2030 bans selling weight-loss and muscle-building supplements to minors; CSPI urges Gov. Newsom to sign to shield children from unsafe products.

Letter to Gavin Newsom RE: AB 2030 (Lowenthal)

"Dear Governor Newsom, The Center for Science in the Public Interest proudly sponsors AB 2030, which would prohibit the sale of over-the-counter diet pills and weight-loss or muscle-building dietary supplements to minors. As the bill passed the legislature on August 27, 2026, we respectfully request you sign the AB 2030 into law." View the resource below to keep reading.

Kennedy’s quiet hunt for autism culprits stalls as Trump orders baseless changes to childhood shots

The Trump administration is working to implement the president’s new order on childhood vaccines, which he publicly faulted for a rise in autism — even as health secretary Robert F. Kennedy Jr.’s closed-door research has yet to produce evidence linking them. Many of Kennedy’s claims so far on autism have not withstood scientific scrutiny.

RFK Jr. leaves GRAS loophole ajar

New Senate Farm Bill text: Small revisions, same threats to food and nutrition security

Comments RE: Pharmacy Compounding Advisory Committee meeting on bulk drug substances nominated for inclusion on the Section 503A bulk drug substance list

"The Center for Science in the Public Interest, an advocacy group that accepts no funding from industry, opposes the proposed inclusion of the seven bulk peptide drug substances (BPC-157, KPV, TB-500, MOTs-C, emideltide, semax, and epitalon) in the 503A Bulks List, allowing them to be compounded, because this action is inconsistent with the FDA’s own standards for pharmacy compounding, poses dangers to consumers, and removes incentives for developing new pharmaceutical products through the standard drug approval process.   Agency scientists recently reviewed the available data for these seven bulk drug substances in detail and recommended that all seven “NOT be included in the 503A Bulks List” (emphasis in the original) because of the overall lack of data to characterize the substances’ historical use, physical and chemical properties, safety profile, and effectiveness. We support the career scientists’ determinations and urge the committee and subsequently the agency itself to follow the recommendations of the FDA’s own subject matter experts. " View the resource below to keep reading.

CSPI condemns DHS public charge rule that will drive eligible families away from nutrition assistance programs